Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells
Metrics: PDF 1681 views | HTML 2104 views | ?
Chengle Zhuang1,2,*, Jianfa Li1,2,*, Yuchen Liu1,*, Mingwei Chen1,3,*, Jiancheng Yuan1, Xing Fu1, Yonghao Zhan1, Li Liu1, Junhao Lin1, Qing Zhou1, Wen Xu1, Guoping Zhao4, Zhiming Cai1, Weiren Huang1
1Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Shenzhen 518039, Guangdong Province, People’s Republic of China
2Shantou University Medical College, Shantou 515041, Guangdong Province, People’s Republic of China
3Anhui Medical University, Hefei 230601, Anhui Province, People’s Republic of China
4Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Centerat Shanghai, Shanghai 200000, Shanghai, People’s Republic of China
*These authors have contributed equally to this work
Weiren Huang, e-mail: email@example.com
Zhiming Cai, e-mail: firstname.lastname@example.org
Keywords: PVT1, bladder cancer, lncRNAs, tetracycline-inducible, synthetic biology
Received: August 07, 2015 Accepted: September 28, 2015 Published: October 15, 2015
Recent studies show that long non-coding RNAs (lncRNAs) may be significant functional regulators in tumor development, including bladder cancer. Here, we found that PVT1 was upregulated in bladder cancer tissues and cells. Further experiments revealed that PVT1 promoted cell proliferation and suppressed cell apoptosis. Furthermore we also used the emerging technology, synthetic biology, to create tetracycline-inducible small hairpin RNA (shRNA) vectors which silenced PVT1 in a dosage-dependent manner to inhibit the progression of bladder cancer. In conclusion, data suggest that PVT1 could be an oncogene and may be a therapeutic target in bladder cancer. Synthetic “tetracycline-on” switch system can be used to quantitatively control the expression of PVT1 in bladder cancer in response to different concentration of doxycycline to suppress the progression of bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.